GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (OTCPK:MEOBF) » Definitions » Valuation Rank

MEOBF (Mesoblast) Valuation Rank


View and export this data going back to 2006. Start your Free Trial

What is Mesoblast Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Mesoblast Valuation Rank Related Terms

Thank you for viewing the detailed overview of Mesoblast's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Mesoblast Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (OTCPK:MEOBF) » Definitions » Valuation Rank
Comparable Companies
ASX:NEU ASX:OPT ASX:CU6 ASX:BOT ASX:PYC ASX:CUV ASX:IMM ASX:OCC ASX:IMU ASX:DXB VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
MESO:USA LWB:Germany LWB:Germany LWB1:Germany LWB:Germany MSB:Australia
Address
55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Website
https://www.mesoblast.com
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.